Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]MNI-952 is a radiopharmaceutical diagnostic agent developed as a positron emission tomography (PET) radioligand for imaging tau protein aggregates in the brain. It is designed to enhance PET imaging by selectively binding to microtubule-associated protein tau, which accumulates abnormally in neurodegenerative diseases such as Alzheimer's disease and progressive supranuclear palsy. The compound contains the radioactive isotope fluorine-18 ([^18F]), enabling visualization of tau pathology in vivo. Its primary use is investigational, aimed at aiding diagnosis and research into tauopathies by providing detailed images of tau distribution and burden within the central nervous system[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]MNI-952.